Charles Bennett to Reverse Transcriptase Inhibitors
This is a "connection" page, showing publications Charles Bennett has written about Reverse Transcriptase Inhibitors.
Connection Strength
0.666
-
Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Feb 01; 35(2):120-5.
Score: 0.219
-
Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med. 2002 Jul 16; 137(2):146-7.
Score: 0.197
-
Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development. Nat Commun. 2020 09 23; 11(1):4737.
Score: 0.174
-
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf. 2009; 32(2):147-58.
Score: 0.077